[Analgesics and their new mechanisms of actions].
Idänpään-Heikkilä
J J
JJ
Helsingin yliopiston biolääketieteen laitos, farmakologian ja toksikologian osasto PL 8 00014 Helsingin yliopisto. heikki.vapaatalo@helsinki.fi
Vapaatalo
H
H
Moilanen
E
E
D058647:Adrenergic alpha-2 Receptor Agonists; D000700:Analgesics / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D065168:Bradykinin Receptor Antagonists; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D009474:Neurons / Q000187:drug effects*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D058906:Purinergic P1 Receptor Agonists; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors; D018042:Receptors, Neurokinin-3 / Q000037:antagonists & inhibitors
D058647:Adrenergic alpha-2 Receptor Agonists; D000700:Analgesics; D065168:Bradykinin Receptor Antagonists; D016861:Cyclooxygenase Inhibitors; D016207:Cytokines; D058906:Purinergic P1 Receptor Agonists; D011949:Receptors, Cholecystokinin; D016194:Receptors, N-Methyl-D-Aspartate; D018041:Receptors, Neurokinin-2; D018042:Receptors, Neurokinin-3; D019001:Nitric Oxide Synthase
Kipulääkkeiden uudet vaikutusmekanismit.